Skip to main content
. 2014 Mar 26;5(21):10342–10355. doi: 10.18632/oncotarget.1867

Figure 2. NSC745885 selectively inhibited cancer cell growth and overcame drug resistance compared to emodin and doxorubicin.

Figure 2

(A) NSC745885 shared a core structure with anthraquinone category drugs like emodin and doxorubicin. (B) The GFP-EZH2 expression of 293T cells treated with DMSO or 5 μM NSC745885 was detected by microscopy. (C) Bladder cancer cells, T24, MBT2, and normal fibroblast 3T3 cells were treated with NSC745885 (2.5 μM) and emodin (40 μM) for 24, 48, and 72 h, respectively. Growth inhibition after NSC745885 treatment compared to emodin treatment was determined by MTT assay (n=3). (D) Growth inhibition by NSC745885 treatment on T24, MBT2, and immortalized normal urothelial cells SV-HUC-1 compared to doxorubicin (2.5 μM) treatment was determined by MTT assay (n=3). (E) Growth inhibition by NSC745885 treatment on MGH-U1 and MGH-U1R cells compared to doxorubicin treatment was determined by MTT assay (n=3). All values were mean±SEM.